AbCellera Results Presentation Deck

FINANCIALS Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 13 $45.9M total revenue, driven by royalties for bebtelovimab. Revenue USD ROYALTIES MILESTONES LICENSING RESEARCH FEES $0.3M $27.6M $21.2M $1.0M $5.2M Q2 2021 $45.9M $33.2M $12.5M Q2 2022 $0.1M

View entire presentation